Evaluation of the efficacy of MaaT013 as rescue therapy in patients with acute GVHD with gastrointestinal involvement, resistant to ruxolitinib; Phase III, multicenter, open-label trial. Maares3
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: MAAT PHARMA
- Phase: III
- Execution start: 31/01/2022
- End of execution: 30/09/2024
- PI: MANUEL JURADO CHACON
